Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
SynopsisH

Increased mortality among elderly patients with dementia using atypical antipsychotics

Sonal Singh and Eric Wooltorton
CMAJ August 02, 2005 173 (3) 252; DOI: https://doi.org/10.1503/cmaj.050478
Sonal Singh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: Atypical antipsychotics are sometimes used to treat the behavioural disturbances (e.g., verbal or physical aggression) and psychotic symptoms that can occur in patients with severe dementia.1 CMAJ has previously issued warnings that specific agents (risperidone, olanzapine) may carry increased risk of fatal and nonfatal cerebrovascular events in patients with dementia.2,3 However, the US Food and Drug Administration (FDA) (www.fda.gov/cder/drug/infopage/antipsychotics/default.htm) and Health Canada (www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/atyp-antipsycho_hpc-cps_e.html) have warned that results from several recent clinical trials suggest the drugs may increase mortality more generally and that this may be a class effect.

The drugs: Atypical antipsychotics, including aripiprazole (Abilify), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), clozapine (Clozaril) and ziprasidone (Geodon), are used to treat schizophrenia. In Canada, only risperidone is indicated for treating behavioural disturbances associated with dementia.

Unfortunately, many of the trials reviewed by the FDA and Health Canada are unpublished, and details in the advisories are sparse (duration of the specific trials, baseline characteristics of the participants, doses used, specific causes of death and confidence intervals around point estimates are not provided). The FDA advisory describes 17 trials involving 5106 patients with dementia taking either placebo or 1 of 4 drugs (olanzapine, aripi prazole, risperidone or quetiapine). The trials averaged 10 weeks in duration. Mean mortality in the treatment group was 4.5% versus 2.6% in the placebo group (a relative risk increase of 1.7). Deaths were mostly due to cardiovascular events or infection. Some summary data from 13 of the trials involving drugs available in Canada are presented in Table 1.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

What to do: Behavioural disturbances in advanced dementia are difficult for everyone to experience, and they seem to have no easy pharmacologic fix. Atypical antipsychotics are of questionable efficacy1,4 and safety in this population. Patients and their families must be warned of the 1.7-fold increase in relative risk of death among those taking these agents over fairly short periods of time (only about 10 weeks). The increase in absolute risk appears to be about 1.9%, giving a number needed to harm of 52. Because the risks of treatment may not be isolated to the first few months of use, the increase in absolute risk over longer treatment periods could be much higher, with much smaller numbers needed to harm. The prevalence of antipsychotic prescriptions translates to an enormous burden of mortality related to these drugs. The risk of death associated with older antipsychotic agents in this population is unclear. Nonpharmacologic measures (education of staff and families, specialized dementia wards) may be preferable ways of managing many behavioural disturbances.

Footnotes

  • Published at www.cmaj.ca on July 13, 2005.

References

  1. 1.↵
    Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004;329:75-8.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167(11):1269-70.
    OpenUrlFREE Full Text
  3. 3.↵
    Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170(9):1395.
    OpenUrlFREE Full Text
  4. 4.↵
    Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA 2005;293:596-608.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 173 (3)
CMAJ
Vol. 173, Issue 3
2 Aug 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Increased mortality among elderly patients with dementia using atypical antipsychotics
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Increased mortality among elderly patients with dementia using atypical antipsychotics
Sonal Singh, Eric Wooltorton
CMAJ Aug 2005, 173 (3) 252; DOI: 10.1503/cmaj.050478

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Increased mortality among elderly patients with dementia using atypical antipsychotics
Sonal Singh, Eric Wooltorton
CMAJ Aug 2005, 173 (3) 252; DOI: 10.1503/cmaj.050478
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Les tasers en medecine : une demande de propositions irreverencieuse
  • Tasers in medicine: an irreverent call for proposals
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Psychiatry & mental health: geriatric
    • Geriatric medicine
    • Dementia & Alzheimer disease

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire